Nitroglycerin plus whole intracranial radiotherapy for brain metastases in non-small cell lung cancer patients: A randomized, open-label, phase II clinical trial.

[1]  R. Wenger,et al.  Interfering with Tumor Hypoxia for Radiotherapy Optimization , 2021, Journal of experimental & clinical cancer research : CR.

[2]  L. Oñate-Ocaña,et al.  Prophylactic Cranial Irradiation in high-risk metastatic non-small cell lung cancer patients: Quality of life and neurocognitive analysis of a randomized phase II study. , 2021, International journal of radiation oncology, biology, physics.

[3]  R. Rosell,et al.  Prophylactic Cranial Irradiation reduces brain metastases and improves overall survival in high-risk metastatic non-small cell lung cancer patients: a randomized phase II study (PRoT-BM trial). , 2021, International Journal of Radiation Oncology, Biology, Physics.

[4]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[5]  P. Brown,et al.  Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Rosell,et al.  Response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status , 2020, Thoracic cancer.

[7]  P. Lambin,et al.  Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial , 2019, Clinical and translational radiation oncology.

[8]  M. Bernstein,et al.  Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases , 2019, Advances in radiation oncology.

[9]  J. Hung,et al.  Combination of Whole-Brain Radiotherapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases , 2019, Cancers.

[10]  O. Arrieta,et al.  Access to lung cancer therapy in the Mexican population: opportunities for reducing inequity within the health system. , 2019, Salud publica de Mexico.

[11]  Yinying Wu,et al.  A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC , 2019, Pathology & Oncology Research.

[12]  N. Forsyth,et al.  Hypoxia-Modified Cancer Cell Metabolism , 2019, Front. Cell Dev. Biol..

[13]  A. Dingemans,et al.  Editorial: Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment , 2018, Front. Oncol..

[14]  D. de Ruysscher,et al.  The Prevention of Brain Metastases in Non-Small Cell Lung Cancer by Prophylactic Cranial Irradiation , 2018, Front. Oncol..

[15]  I. Amelio,et al.  The hypoxic tumour microenvironment , 2018, Oncogenesis.

[16]  R. Lewensohn,et al.  Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer , 2017, Acta oncologica.

[17]  P. Brown,et al.  Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA) , 2017, JAMA oncology.

[18]  Jing Yang,et al.  First‐line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR‐mutated lung adenocarcinoma , 2016, Cancer science.

[19]  A. Amini,et al.  Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  J. Overgaard,et al.  The impact of hypoxia and its modification of the outcome of radiotherapy , 2016, Journal of radiation research.

[21]  Jian-Li Hu,et al.  Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis , 2016, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

[22]  T. Jiang,et al.  Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis , 2016, Cancer medicine.

[23]  H. Groen,et al.  A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  D. Costa,et al.  Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. , 2015, Lung cancer.

[25]  Wolfgang A Tome,et al.  Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Stockler,et al.  A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  N. Reinmuth,et al.  Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC). , 2014, Lung cancer.

[28]  J. Markowitz,et al.  Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer , 2013, Journal of Immunotherapy for Cancer.

[29]  P. Ruth,et al.  Ionizing radiation, ion transports, and radioresistance of cancer cells , 2013, Front. Physiol..

[30]  L. Ting,et al.  EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases , 2012, Radiation oncology.

[31]  Dirk Rades,et al.  Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline , 2012, Practical radiation oncology.

[32]  A. Sikora,et al.  Tumor-Expressed Inducible Nitric Oxide Synthase Controls Induction of Functional Myeloid-Derived Suppressor Cells through Modulation of Vascular Endothelial Growth Factor Release , 2012, The Journal of Immunology.

[33]  A. Mohar,et al.  Whole-brain irradiation with concomitant daily fixed-dose temozolomide for brain metastases treatment: a randomised phase II trial. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[34]  D. Kondziolka,et al.  The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline , 2009, Journal of Neuro-Oncology.

[35]  H. Kubo,et al.  Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Dewhirst,et al.  Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. , 2005, Cancer cell.

[37]  Yue Cao,et al.  Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Dewhirst,et al.  Raising the Bar: How HIF-1 Helps Determine Tumor Radiosensitivity , 2004, Cell cycle.

[39]  M. Dewhirst,et al.  Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. , 2004, Cancer cell.

[40]  Thilo Hagen,et al.  Redistribution of Intracellular Oxygen in Hypoxia by Nitric Oxide: Effect on HIF1α , 2003, Science.

[41]  A. Zajícová,et al.  Nitric oxide as a regulatory and effector molecule in the immune system. , 2002, Molecular immunology.

[42]  Christian Bogdan,et al.  Nitric oxide and the immune response , 2001, Nature Immunology.

[43]  G. Semenza,et al.  HIF-1 and human disease: one highly involved factor. , 2000, Genes & development.

[44]  G. Semenza,et al.  Carbon Monoxide and Nitric Oxide Suppress the Hypoxic Induction of Vascular Endothelial Growth Factor Gene via the 5′ Enhancer* , 1998, The Journal of Biological Chemistry.

[45]  C. Bogdan.  Regulation of lymphocytes by nitric oxide. , 2011, Methods in molecular biology.

[46]  K. O'Byrne,et al.  Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer. , 2006, Clinical lung cancer.